PATIENT ALERT: Information regarding COVID-19. 

Clinical Research & Trials

MERCK KEYLYNK MK7339-009

An Open-label, Randomized, Phase 2/3 Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction of Clinical Benefit with First-line Chemotherapy Plus Pembrolizumab in Participants with Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (TNBC)(KEYLYNK-009)

 

Disease Types: Breast Cancer Research

Eligibility Requirements:

-locally inoperable or metastatic breast cancer with measurable disease, not previously treated in the metastatic setting
-must be able to tolerate and absorb oral medication
-No: active CNS metastasis or carcinomatous meningitis; immunodeficiency; condition requiring chronic systemic steroid therapy; non-infectious pneumonitis, interstitial lung disease, known history of HIV or Hep B, or known active Hep C or tuberculosis;
allogenic tissue, organ, bone marrow, or umbilical cord transplant; congestive heart failure II-IV or MI in last 6 months
-No: prior therapy with olaparib or other PARP inhibitor; prior therapy with anti PD-1, PD-L1, PD-L2, CTLA-4, OX-40, or CD137 agents

Available at: